Therapeutic Alemtuzumab antibody from the original Lemtrada® commercial drug.

Showing the single result

Filter our product list:
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Expiry Date
Filters Sort results
Reset Apply


Molecular Class
Drug Brand
Product Concentration
Quantity per vial
Storage Temperature
Expiry Date
Price from
Monoclonal Antibody
10 mg/mL
0,5 mg
view product
Max: 10
Min: 1
Step: 1

Not looking for Alemtuzumab?

Search our therapeutic molecules product database

Lemtrada® / Alemtuzumab Reference Product

Drug nameLemtrada®
API typeAlemtuzumab is a monoclonal antibody produced in mammalian cell (Chinese Hamster Ovary) suspension culture in a nutrient medium by recombinant DNA technology.
Pharmacotherapeutic group
Selective immunosuppressants
ATC code
Target of antibody
General functionAlemtuzumab binds to CD52, a cell surface antigen present at high levels on T (CD3+) and B (CD19+) lymphocytes, and at lower levels on natural killer cells, monocytes, and macrophages. There is little or no CD52 detected on neutrophils, plasma cells, or bone marrow stem cells. Alemtuzumab acts through antibody-dependent cellular cytolysis and complement-mediated lysis following cell surface binding to Tand B lymphocytes.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Alemtuzumab, is a recombinant DNA-derived humanised monoclonal antibody directed against the
21-28 kD cell surface glycoprotein CD52. Alemtuzumab is an IgG1 kappa antibody with human variable
framework and constant regions, and complementary-determining regions from a murine (rat) monoclonal
antibody. The antibody has an approximate molecular weight of 150 kD.

Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Alemtuzumab depletes circulating T and B lymphocytes after each treatment course with the lowest observed
values occurring 1 month after a course of treatment (the earliest post-treatment time point in phase 3
studies). Lymphocytes repopulate over time with B-cell recovery usually completed within 6 months. CD3+
and CD4+ lymphocyte counts rise more slowly towards normal, but generally do not return to baseline by
12-months post-treatment. Approximately 40% of patients had total lymphocyte counts reaching the lower
limit of normal (LLN) by 6 months after each treatment course, and approximately 80% of patients had total
lymphocyte counts reaching the LLN by 12 months after each course.
Original license holder
Sanofi Belgium
Leonardo Da Vincilaan 19
B-1831 Diegem
Marketing authorisation numbers

Marketing authorisation holder
Sanofi Belgium
Leonardo Da Vincilaan 19
B-1831 Diegem
Name of the manufacturer of the biological active substance
Boehringer Ingelheim Pharma GmbH & Co. KG
Birkendorfer Straße 65
88397 Biberach an der Riss
Name and address of the manufacturer(s) responsible for batch releaseGenzyme Ireland Limited
IDA Industrial Park
Old Kilmeaden Road
Max shelf life
3 years
Storage conditions
2°C – 8°C
List of excipients
Disodium phosphate dihydrate (E339)
Disodium edetate
Potassium chloride (E508)
Potassium dihydrogen phosphate (E340)
Polysorbate 80 (E433)
Sodium chloride
Water for injections